For our latest Special Report, Adriaan Fruijtier from CATS Consultants, gives an account of major talking points at one of the year’s major events in the calendar of the Regulatory Affairs Professionals Society (RAPS), which took place in Brussels earlier in the summer.
Brexit
There was a lot of interest in this session. The first speaker was Marie-Helene Pinheiro, principal regulatory advisor at the European Medicines Agency (EMA), who spoke about the consequences of Brexit for the EMA and the products in the Centralized Procedure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze